Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting

2022-502597-16-00 Intermediate or High-risk Primary or Secondary Myelofib 2023-10-27
Clofarabine Therapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: a Phase 1/2 Dose-Escalation Study Recruiting

2024-516586-37-00 Urothelial carcinoma 2023-10-24
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons with Severe or Moderate … Recruiting

2023-503906-35-00 Severe or Moderate Hemophilia A with or without factor 2023-10-11
Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseas… Recruiting

2024-514433-38-00 fibrotic interstitial lung disease 2023-09-28
Can a single dose of psilocybin reduce alcohol intake in patients with alcohol use disorder? Recruiting

2024-517497-17-01 Alcohol Use Disorder 2023-09-01
A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatr… Recruiting

2024-511336-28-00 Leukemia in childhood 2023-08-11
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients … Recruiting

2022-501822-39-00 Glioblastoma 2023-07-31
Phase I/II study with galunisertib combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer with perito… Recruiting

2024-518980-37-00 colorectal cancer 2023-07-12
Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa)… Recruiting

2024-511794-30-00 Multiple Myeloma 2023-06-28
A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici… Recruiting

2023-507171-22-00 Untreated Advanced or Metastatic Non-Small Cell Lung Ca 2023-06-21
Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leuke… Recruiting

2024-514688-24-00 Patients with myelodysplastic syndrome (MDS), chronic m 2023-05-26
Phase I/II Study of inducible HLAG+ Regulatory T Cells (iG-Tregs) in patients undergoing HLA-matched sibling donor allogeneic haematopoietic… Recruiting

2024-520084-14-00 Adopt immunotherapy in adult patients undergoing hemato 2023-05-26
A Study of Debio 0123 in Combination with Temozolomide in Adult Participants with Recurrent or Progressive Glioblastoma and of Debio 0123 in… Recruiting

2022-502156-31-00 Glioblastoma 2023-05-26
This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran… Recruiting

2024-512878-98-00 Brain Metastasis from Estrogen Receptor Positive, HER-2 2023-05-16
CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE Recruiting

2024-516819-24-00 Systemic Sclerosis 2023-05-16
Platform study of JDQ443 in combinations in patients with advanced solid tumors harboring the KRAS G12C mutation Recruiting

2023-506716-41-00 Adult patients with advanced (metastatic or unresectabl 2023-05-08
Study to evaluate the ability of a sublingual vaccine to induce the expression of trained immunity in peripheral blood cells Recruiting

2024-516720-34-00 Healthy adult males and non-pregnant females 2023-03-31
Study of Combination Therapies in Esophageal Cancer Recruiting

2023-505189-26-00 Advanced esophageal squamous cell carcinoma 2023-03-28
A study investigating the use of EP0031 in patients with cancers having an abnormal RET gene. Recruiting

2022-501636-42-00 Advanced RET-altered malignancies 2023-03-21
Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102 Recruiting

2022-501082-52-00 Fanconi anemia subtype A (FA-A) 2023-03-01
68Ga-SATO antagonist in neuroblastoma Recruiting

2024-513843-10-00 neuroblastoma 2023-02-28
phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate… Recruiting

2024-511631-10-00 Hodgkin’s lymphoma 2023-02-27
A Trial to Evaluate EP 104GI in Adults with Eosinophilic Esophagitis (EoE) (RESOLVE) Recruiting

2024-516689-13-00 Eosinophilic esophagitis 2023-02-06
Phase 1b/2a Study to Evaluate CC-92480 (BMS-986348) in Combination with Other Treatments in Relapsed or Refractory Multiple Myeloma Recruiting

2023-509384-25-00 Relapsed or Refractory Multiple Myeloma (RRMM) 2022-12-30